RecruitingNCT06377592
Development and Accuracy Evaluation of Gram Staining Analysis AI
Sponsor
GramEye
Enrollment
18,000 participants
Start Date
May 10, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The investigators use Gram-stained specimens provided from clinical settings to develop and evaluate the accuracy of Gram staining analysis AI
Eligibility
Inclusion Criteria1
- Patients in whom a Gram stain test was ordered
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERSample collection without intervention
No Intervention
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06377592
Related Trials
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
NCT0564510762 locations
Healthrelated Quality of Life and Experiences of a Heart Rehabilitation Programme After Care for Infective Endocarditis.
NCT067040481 location
A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
NCT070177773 locations
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
NCT042637921 location
A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women
NCT065925866 locations